ROC curve analysis was used to evaluate the performance of CTSF and FBLN1 as serum biomarkers for diagnosing NSCLC BM, compared with the classical serum biomarkers for lung cancer (CEA, CA125, SCC, CYFRA211). This evidence concerns the gene CEACAM5 and lung carcinoma.